Abstract: Alteration of antigen recognition by T cells as result of insufficient major histocompatibility complex (MHC)-dependent antigen-presenting function has been observed in many cases of infections, particularly in in vitro systems. To hide themselves from an efficient immune response, pathogens may act on MHC-related functions at three levels: (i) by limiting the number of potential antigens that can be presented to naïve T cells; (ii) by synthesizing proteins which directly affect MHC cell-surface expression; and (iii) by altering the normal intracellular pathway of peptide loading on MHC. Here, we review examples of pathogens' action on each single step of MHC function and we suggest that the result of these often synergistic actions is both a limitation of the priming of naïve T cells and, more importantly, a protection of the pathogen's reservoir from the attack of primed T cells. The above mechanisms may also generate a skewing effect on immune effector mechanisms, which helps preserving the reservoir of infection from sterilization by the immune system.
In medical practice, it is frequently observed that an infectious disease, effectively controlled at clinical level, is not fully controlled at microbiological level because the infectious agent cannot be eradicated by the combined action of therapeutic treatment and immune response. The potential of some microbes to persist endlessly in the host is a dramatic evidence of the accomplishment of strategies to elude the immune response. Apparently, no particular phase or arm of the vertebrate immune response is entirely safe from pathogenevasion strategies. Indeed, microbes exhibit an extremely sophisticated biotechnological skill in the interactions with the host (1). In particular, in vitro analysis of host-pathogen interactions has revealed a plethora of alterations affecting both the expression and the function of major histocompatibility complex (MHC) molecules, the cell-surface receptors which bind and present antigenic peptides to T lymphocytes. MHC class I molecules, expressed on virtually all nucleated cells, bind peptides from endogenously synthesized proteins and present them to CD8 For example, we have observed an increase in surface MHC-I molecules in macrophage phagocytosing a broad range of bacteria (6; A.
De Lerma Barbaro, unpublished data). This overexpression is not related to a direct effect of the infectious particle or to soluble substances (toxins) of microbial origin; instead, it is the result of autocrine factors produced by the cell itself.
In sharp contrast to MHC-I, MHC-II pathway can be altered by a wide array of pathogens including viruses, intracellular, and extracellular bacteria as well as protozoa and multicellular parasites (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . Given the role of MHC-II molecules in triggering the Th Pathogens' strategies to limit and/or elude priming of naïve T cells
It is intriguing that primary T-cell responses against pathogens are often directed against a small number of pathogens' gene products (16) .
A clear picture of the cellular and molecular events leading to the above phenomenon is still incomplete. Nevertheless, a series of findings point to the important role of dendritic cells (DCs) and their MHC molecules.
DCs are the main APCs for priming naïve T cells. DC engulf the antigen in the periphery, process it, and become functionally mature while migrating to secondary lymphoid organs where they meet and stimulate T cells (17) . It has been found that some viruses can provoke a functional paralysis of DC maturation (18) . Furthermore, certain viruses encode ORFs whose products directly affect the MHC-I expression pathway. It is likely that the above events can produce a restriction in the number of pathogen's products effectively available for priming (19) .
Herpesviruses are an attractive model system to elucidate the antigen-presentation capacity (25, 26) , and both herpesvirus encode the most efficient inhibitors of MHC-I pathway described so far (3).
On the contrary, the CD8 þ CTL repertoire against the proteoma of both influenza A virus and EBV is broad. During human flu infections, it is possible to find CTL responses directed against six of the 10 proteins encoded by the virus (27) . In mice, a wide-ranging analysis of antigenic peptides from influenza A PR8 strain proteome has shown CTL responses directed against 10 of the 11 viral products (28) . Similar findings have been described for EBV infections:
among six viral products analyzed, two IE antigens and three E antigens elicit CD8 þ T responses (29) . These two viruses do not interfere directly with the MHC-I pathway, although the EBNA from EBV impairs its own proteasome-mediated degradation preventing formation of peptides that may be bound by MHC-I molecules (30).
Importantly, both influenza virus and EBV do not inhibit functional maturation of DC (31, 32) .
The correlations summarized in Table 1 
Identification of the cellular reservoir of infection
It has been argued that the goal of intracellular pathogens is not to kill the cell host, but to replicate and spread to an extent compatible with survival of both pathogen and host. Therefore, the maintenance of a cellular reservoir (Fig. 1B) Fig. 2) . In fact, these cells need recognition of MHC-II-peptide complex to be stimulated but have less requirements than naïve T cells for accessory costimuli (14, 37) . Within this frame, it should be stressed that pathogen-mediated MHC-II downregulation in APCs may affect a major effector function of Th-1 cells, the production of interferon-gamma (IFN-g), whose microbicidal activity within the reservoir of infection has been firmly established (38) . (43) should be also considered. Human: six viral products (27) Viral genome encodes only 10 proteins
Correlation between viral infection of dendritic cells (DCs), their antigen-presenting cell (APC) function, and MHC-I-restricted response of immune cytolytic T lymphocytes (CTL) effector cells
Mouse: 10 viral products (28) Viral genome encodes only eleven proteins Table 1 De 
Conclusions and future perspectives
Interference of infectious agents on the MHC-I and MHC-II pathways may play a relevant role in vivo not only in preventing T-cell priming but, more importantly, in hiding and protecting the cellular reservoirs of infection from sterilization. Future studies focused on the connection between molecular aspects (i.e., ORFs that impair MHC function), and cellular events (the interaction between the pathogen and the APC, as well as the T-cell repertoire effectively stimulated)
will be instrumental to better clarify host-pathogen interaction during infectious diseases.
Moreover, it will be of paramount importance to elucidate the role of 'ectopic' expression of MHC-II in vivo in non-professional APCs that can be reservoir of intracellular pathogens. Within this frame, more emphasis should be given to the identification of MHC-II immunoevasins. HCMV encodes the three major viral MHC-II immunoevasins identified to date, namely U2, U11, and U3, and it is interesting to note that these molecules affect MHC-I pathway as well. Unfortunately, since a suitable animal model for HCMV infection is lacking, it is not possible to study the in vivo relevance of these genes by deletion analysis (58) . Microbes bearing a transgenic GFP (59) can be used to identify infectious particles in tissues, the relative pathogen load in cells of the affected tissue, and the corresponding expression of MHC-II molecules. The targeted inactivation of the promoter IV of the AIR-1 gene encoding the MHC-II transactivator (CIITA) (60, 61) produces mice whose putative APCs of non-hematopietic origin cannot be induced by IFN-g for MHC-II expression (62) . These mice could be a valuable in vivo model to study the relevance of MHC-II inducibility in the clinical course of infections by some intracellular pathogens such as chlamydia, salmonella, and CMV that colonize cellular reservoirs distinct from macrophages.
These studies will increase the knowledge of the pathogen-host interactions and will contribute to the design of novel strategies for vaccine production.
